Success Metrics

Clinical Success Rate
58.3%

Based on 7 completed trials

Completion Rate
58%(7/12)
Active Trials
0(0%)
Results Posted
143%(10 trials)
Terminated
5(38%)

Phase Distribution

Ph phase_1
2
15%
Ph phase_2
1
8%
Ph phase_3
10
77%

Phase Distribution

2

Early Stage

1

Mid Stage

10

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
2(15.4%)
Phase 2Efficacy & side effects
1(7.7%)
Phase 3Large-scale testing
10(76.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

53.8%

7 of 13 finished

Non-Completion Rate

46.2%

6 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(7)
Terminated(6)

Detailed Status

Completed7
Terminated5
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
58.3%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (15.4%)
Phase 21 (7.7%)
Phase 310 (76.9%)

Trials by Status

terminated538%
withdrawn18%
completed754%

Recent Activity

0 active trials
Showing 5 of 13
terminatedphase_3

Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

NCT03614156
terminatedphase_3

Study of Rapastinel as Monotherapy in Patients With MDD

NCT03560518
terminatedphase_2

A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

NCT03352453
terminatedphase_3

Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)

NCT03675776
terminatedphase_3

Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)

NCT03668600
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT03614156Phase 3

Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

Terminated
NCT03560518Phase 3

Study of Rapastinel as Monotherapy in Patients With MDD

Terminated
NCT03352453Phase 2

A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

Terminated
NCT03675776Phase 3

Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)

Terminated
NCT03668600Phase 3

Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)

Terminated
NCT03002077Phase 3

Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

Completed
NCT02951988Phase 3

A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder

Completed
NCT02943564Phase 3

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)

Completed
NCT02943577Phase 3

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)

Completed
NCT02932943Phase 3

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)

Completed
NCT03855865Phase 3

Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)

Withdrawn
NCT03814733Phase 1

Assessment of Effect of Rapastinel on Driving Performance

Completed
NCT03799900Phase 1

Assessment of Abuse Potential of Rapastinel in Humans

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13